Vitamin D treatment effect on retinal nerve fiber loss after optic neuritis.

There is accumulating evidence for a possible protective role of vitamin D in the development and disease course of multiple sclerosis (MS). Vitamin D is cheap, easy to administer, and safe. However, intervention studies are scarce and increasingly difficult to perform.

The first presenting symptom of MS is often optic neuritis (ON). Studies in MS and ON patients show a decrease in retinal nerve fiber layer (RNFL) thickness and macular volume, occurring within 1-3 months after ON. RNFL thickness can accurately be measured using optical coherence tomography (OCT): a novel and robust diagnostic tool. The rapid changes in RNFL after acute ON make it useful for testing neuroprotective strategies over a short time frame. Other advantages of using ON patients to study the effect of vitamin D treatment include the possibility of starting early in the pathology, a relatively large availability of eligible patients because of the infrastructure and experience of our MS center. Finally, the well-defined symptom-onset makes it a relatively homogenous group.



We hypothesize that vitamin D treatment reduces axonal loss in ON patients primarily by its properties to modulate inflammation, and perhaps also by its neuroprotective properties.



The primary endpoint of this study is retinal nerve fiber layer thickness in ON patients with either vitamin D treatment or placebo, as measured by OCT. Other endpoints include effects of vitamin D on occurrence of second attack, visual outcome, clinical outcome and biomarkers in blood and cerebrospinal fluid.



We will conduct a double-blind randomized placebo controlled trial. Patients with unilateral optic neuritis will be randomized to receive either vitamin D (14.000 IU/week) or placebo. Follow-up will be 2 years. OCT, collection of blood and cerebrospinal fluid, clinical assessment and visual testing will be performed at regular time points.



Vitamin D intervention studies are urgently needed. This protocol is innovative in using a novel, accurate diagnostic tool in a well-defined patient group.

There is accumulating evidence for a possible protective role of vitamin D in the development and disease course of multiple sclerosis (MS). Vitamin D is cheap, easy to administer, and safe. However, intervention studies are few.
The first presenting symptom of MS is often optic neuritis (ON). Studies in MS and ON patients show a decrease in retinal nerve fiber layer (RNFL) thickness and macular volume, occurring within 1-3 months after ON. RNFL thickness can accurately be measured using optical coherence tomography (OCT): a novel and robust diagnostic tool. The objective of this trial is to test the hypothesis that vitamin D treatment reduces axonal loss in ON patients, as measured by OCT.

1. OCT will be performed at baseline, 6 months, 1 year and 2 years;

2. Lumbar puncion and MRI will be performed at baseline and 2 years;

3. Clinical and visual testing will be performed at baseline, 6 months, 1 year and 2 years;

4. Blood samples will be collected every 3 months.

Patients with unilateral optic neuritis will be randomly assigned to receive either vitamin D3 (Cholecalciferol) as an oral liquid medicine (14.000 IU/week) or placebo. Study medication will be administered once a week for 2 years.